ASX · NEU.AX
Neuren Pharmaceuticals Limited
A$20.48+A$0.34 (+1.69%)
Neuren Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 13.8% below the high.
Loading market information…
ASX · ATH.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 03:36 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 68.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Alterity Therapeutics Limited’s next earnings report is currently expected on Mar 4, 2027, with estimated earnings per share of -A$0.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alterity Therapeutics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2024 | Feb 28, 2024 | -A$0.13-712.5% vs estimate | A$118.40K-91.86% vs estimate |
|---|
| Q4 2023 | Aug 31, 2023 | -A$0.12-566.67% vs estimate | A$1.53M-32.49% vs estimate |
|---|
| Q2 2023 | Feb 28, 2023 | -A$0.17+40.0% vs estimate | A$11.38K-99.59% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$20.48+A$0.34 (+1.69%)
Neuren Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 13.8% below the high.
A$0.04-A$0.00 (-4.65%)
Actinogen Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 43.06% below the high.
A$0.47-A$0.02 (-3.67%)
Nyrada Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.22% below the high.
A$0.92+A$0.02 (+2.22%)
Ceretas Limited’s quoted price sits in the upper half of its reported 52-week range, 17.12% below the high.
A$0.09A$0.00 (0.0%)
Neurizon Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 31.2% below the high.
A$0.05+A$0.00 (+3.92%)
Arovella Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 47.0% below the high.
A$0.05A$0.00 (0.0%)
NeuroScientific Biopharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
A$0.12+A$0.01 (+9.52%)
Argenica Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
